IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis
Wang, Y.; Liu, D-H; Xu, L-P; Liu, K-Y; Chen, H.; Zhang, X-H; Chen, Y-H; Han, W.; Wang, F-R; Wang, J-Z; Yan, C-H; Huang, X-J
关键词Donor Lymphocyte Infusion Relapse Hla-mismatched
刊名BONE MARROW TRANSPLANTATION
2012-08-01
DOI10.1038/bmt.2011.213
47期:8页:1099-1104
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]BONE-MARROW-TRANSPLANTATION ; DONOR LYMPHOCYTE INFUSION ; ACUTE MYELOID-LEUKEMIA ; COLONY-STIMULATING FACTOR ; ACUTE GVHD ; BLOOD ; FEASIBILITY ; PROPHYLAXIS ; THERAPY ; GRAFTS
英文摘要

The role of donor lymphocyte infusion (DLI) in the prophylaxis of relapse has not been defined. We retrospectively analyzed the data from 88 patients with advanced-stage acute leukemia after HLA-mismatched/haploidentical hematopoietic SCT (HSCT) whose treatment did (n=61) or did not (n=27) include granulocyte CSF (GCSF)-primed PBPCs infusion (GPBPCI). The two groups were compared with respect to relapse and OS. Further, a detailed analysis of risk factors was performed. The 2-year cumulative incidence of relapse in patients receiving prophylactic GPBPCI and not receiving prophylactic GPBPCI were 36% and 55% (P=0.017), respectively. Estimated survival at 3 years was 31% for patients receiving prophylactic GPBPCI and 11% for patients not receiving prophylactic GPBPCI (P=0.001). The three-year probability of leukemia-free survival was also higher in patients who received prophylactic GPBPCI (22%) compared with patients who did not (11%) (P=0.003). Multivariate analysis for relapse showed that use of prophylactic GPBPCI after transplantation was an independent prognostic factor (P=0.025). Higher OS was associated with use of prophylactic GPBPCI (P=0.002), AML (P=0.027) and female sex (P=0.023). Our results suggest that use of prophylactic GPBPCI may increase survival of patients with advanced-stage acute leukemia who receive HLA-mismatched/haploidentical HSCT.

语种英语
WOS记录号WOS:000307648300013
项目编号30971292 ; 2008zx09312-026
资助机构National Natural Science Foundation of China ; National High-tech R&amp ; D Program of China (863 Program) ; Ministry of Health of China ; National Scientific Major Program-major new drug formulation ; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation
引用统计
被引频次:28[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52355
专题北京大学第二临床医学院_血液科
医学人文研究院/公共教学部_哲学与社会科学系
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Wang, Y.,Liu, D-H,Xu, L-P,et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis[J]. BONE MARROW TRANSPLANTATION,2012,47(8):1099-1104.
APA Wang, Y..,Liu, D-H.,Xu, L-P.,Liu, K-Y.,Chen, H..,...&Huang, X-J.(2012).Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis.BONE MARROW TRANSPLANTATION,47(8),1099-1104.
MLA Wang, Y.,et al."Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis".BONE MARROW TRANSPLANTATION 47.8(2012):1099-1104.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Y.]的文章
[Liu, D-H]的文章
[Xu, L-P]的文章
百度学术
百度学术中相似的文章
[Wang, Y.]的文章
[Liu, D-H]的文章
[Xu, L-P]的文章
必应学术
必应学术中相似的文章
[Wang, Y.]的文章
[Liu, D-H]的文章
[Xu, L-P]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。